Algeta Initiates New Oncology Research Program to Conjugate Thorium-227 to Epratuzumab

News   Jan 29, 2013

 
Algeta Initiates New Oncology Research Program to Conjugate Thorium-227 to Epratuzumab
 
 
 

RELATED ARTICLES

Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of London

News

The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.

READ MORE

Scientists Reveal the Relationship Between Sugar and Cancer

News

By analysisng metabolites scientists have clarified how the Warburg effect, a phenomenon in which cancer cells rapidly break down sugars, stimulates tumor growth.

READ MORE

APEIRON Strengthens Management Board

News

Industry expert Peter Llewellyn-Davies joins as New Chief Financial Officer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE